What is Inmune Bio Inc's earnings per share (EPS)?

Inmune Bio Inc (INMB) reported diluted earnings per share of $-1.86 for fiscal year 2025. This represents a 11.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Inmune Bio Inc Financials

INMB

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows Inmune Bio Inc (INMB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.49x

For every $1 of reported earnings, Inmune Bio Inc generates $0.49 in operating cash flow (-$22.6M OCF vs -$45.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$50K

YoY+257.1%

5Y CAGR+35.4%

Inmune Bio Inc generated $50K in revenue in fiscal year 2025. This represents an increase of 257.1% from the prior year.

EBITDA

-$47.3M

Inmune Bio Inc's EBITDA was -$47.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

-$45.9M

YoY-9.2%

Inmune Bio Inc reported -$45.9M in net income in fiscal year 2025. This represents a decrease of 9.2% from the prior year.

EPS (Diluted)

$-1.86

YoY+11.8%

Inmune Bio Inc earned $-1.86 per diluted share (EPS) in fiscal year 2025. This represents an increase of 11.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$23.6M

Inmune Bio Inc generated -$23.6M in free cash flow in fiscal year 2025, representing cash available after capex.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

27M

YoY+19.3%

5Y CAGR+14.5%

Inmune Bio Inc had 27M shares outstanding in fiscal year 2025. This represents an increase of 19.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-94766.0%

YoY+209769.7pp

5Y CAGR+16397.6pp

Inmune Bio Inc's operating margin was -94766.0% in fiscal year 2025, reflecting core business profitability. This is up 209769.7 percentage points from the prior year.

Net Margin

-91866.0%

YoY+208719.7pp

5Y CAGR+18124.9pp

Inmune Bio Inc's net profit margin was -91866.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 208719.7 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$20.7M

YoY-37.7%

5Y CAGR+28.4%

Inmune Bio Inc invested $20.7M in research and development in fiscal year 2025. This represents a decrease of 37.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.0M

Inmune Bio Inc invested $1.0M in capex in fiscal year 2025, funding long-term assets and infrastructure.

INMB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$50K+257.1%	$14K-91.0%	$155K-58.6%	$374K+106.6%	$181K+1545.5%	$11K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$20.7M-37.7%	$33.2M+63.6%	$20.3M+18.8%	$17.1M-16.9%	$20.5M+247.1%	$5.9M
SG&A Expenses	$10.3M+8.2%	$9.5M-1.5%	$9.6M+3.9%	$9.3M+5.3%	$8.8M+39.1%	$6.3M
Operating Income	-$47.4M-11.1%	-$42.6M-43.4%	-$29.7M-14.6%	-$26.0M+11.0%	-$29.2M-138.4%	-$12.2M
Interest Expense	$0-100.0%	$357K-84.3%	$2.3M+13.1%	$2.0M+104.5%	$985K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$45.9M-9.2%	-$42.1M-40.2%	-$30.0M-9.9%	-$27.3M+10.0%	-$30.3M-150.8%	-$12.1M
EPS (Diluted)	$-1.86+11.8%	$-2.11-26.3%	$-1.67-9.9%	$-1.52+19.1%	$-1.88	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	$50K	N/A	N/A	N/A	$14K-50.0%	$28K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.9M-15.8%	$5.8M-24.0%	$7.6M	N/A	$10.1M+42.7%	$7.1M-18.9%	$8.7M+44.7%	$6.0M
SG&A Expenses	$2.5M+13.0%	$2.3M-2.7%	$2.3M	N/A	$2.2M-21.1%	$2.8M+20.3%	$2.3M-2.6%	$2.4M
Operating Income	-$7.4M+69.7%	-$24.6M-148.1%	-$9.9M	N/A	-$12.3M-24.5%	-$9.9M+10.5%	-$11.0M-31.5%	-$8.4M
Interest Expense	N/A	$250K	$0	N/A	$145K-42.0%	$250K-30.0%	$357K-23.6%	$467K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.5M+73.5%	-$24.5M-151.1%	-$9.7M	N/A	-$12.1M-24.1%	-$9.7M+11.6%	-$11.0M-31.1%	-$8.4M
EPS (Diluted)	$-0.24+77.1%	$-1.05-144.2%	$-0.43	N/A	$-0.60-20.0%	$-0.50+18.0%	$-0.61	N/A

INMB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$39.6M-30.6%	$57.0M-30.3%	$81.8M-18.2%	$99.9M+145.8%	$40.7M
Current Assets	N/A	$22.7M-43.3%	$39.9M-38.2%	$64.7M-21.7%	$82.6M+244.4%	$24.0M
Cash & Equivalents	N/A	$20.9M-41.6%	$35.8M-31.3%	$52.2M-30.3%	$74.8M+240.6%	$22.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$1.2M-38.0%	$1.9M	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$7.5M-60.4%	$18.9M-13.0%	$21.7M+10.0%	$19.7M+936.8%	$1.9M
Current Liabilities	N/A	$7.2M-60.9%	$18.5M+69.1%	$10.9M+150.5%	$4.4M+145.4%	$1.8M
Long-Term Debt	N/A	$15.0M	N/A	$9.7M-35.4%	$15.0M	N/A
Total Equity	N/A	$32.1M-14.0%	$37.3M-37.9%	$60.1M-25.1%	$80.2M+107.0%	$38.8M
Retained Earnings	N/A	-$163.1M-34.8%	-$121.0M-33.0%	-$91.0M-42.8%	-$63.7M-90.9%	-$33.4M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$33.4M-11.5%	$37.7M-0.3%	$37.8M-4.5%	$39.6M-25.0%	$52.8M+0.6%	$52.5M+12.0%	$46.8M-17.8%	$57.0M
Current Assets	$30.7M-14.9%	$36.0M+71.9%	$21.0M-7.5%	$22.7M-36.8%	$35.9M+1.0%	$35.5M+19.0%	$29.8M-25.3%	$39.9M
Cash & Equivalents	$27.7M-16.9%	$33.4M+72.6%	$19.3M-7.6%	$20.9M-37.6%	$33.6M+8.0%	$31.1M+19.5%	$26.0M-27.5%	$35.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.7M+6.2%	$1.6M+25.1%	$1.3M+8.6%	$1.2M+6.5%	$1.1M-64.7%	$3.1M	N/A	$1.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.0M-9.5%	$8.8M+8.5%	$8.1M+8.9%	$7.5M-47.1%	$14.1M-8.2%	$15.4M-13.7%	$17.8M-5.6%	$18.9M
Current Liabilities	$7.4M-14.3%	$8.6M+8.3%	$7.9M+9.8%	$7.2M-47.8%	$13.8M-8.2%	$15.1M-13.7%	$17.4M-5.5%	$18.5M
Long-Term Debt	N/A	$15.0M0.0%	$15.0M0.0%	$15.0M	N/A	N/A	N/A	N/A
Total Equity	$25.4M-12.1%	$28.9M-2.7%	$29.7M-7.6%	$32.1M-17.0%	$38.7M+6.6%	$36.3M+28.5%	$28.2M-24.4%	$37.3M
Retained Earnings	-$203.8M-3.3%	-$197.3M-14.2%	-$172.8M-6.0%	-$163.1M-6.0%	-$153.9M-8.5%	-$141.8M-7.4%	-$132.0M-9.1%	-$121.0M

INMB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$22.6M+32.3%	-$33.4M-178.5%	-$12.0M+47.2%	-$22.7M+20.4%	-$28.5M-218.7%	-$8.9M
Capital Expenditures	$1.0M	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$23.6M	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$1.0M	N/A	N/A	N/A	-$15.0M	N/A
Financing Cash Flow	$27.6M+51.6%	$18.2M+531.0%	-$4.2M-679.6%	$729K-99.2%	$96.4M+303.3%	$23.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$5.4M+26.3%	-$7.4M-8.1%	-$6.8M+38.0%	-$11.0M-57.6%	-$7.0M+11.4%	-$7.9M-5.5%	-$7.5M-119.8%	-$3.4M
Capital Expenditures	$193K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$5.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$193K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$0-100.0%	$22.3M+322.3%	$5.3M+353.8%	-$2.1M-121.2%	$9.8M-24.7%	$13.0M+619.9%	-$2.5M0.0%	-$2.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

INMB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-94766.0%+209769.7pp	-304535.7%-285348.0pp	-19187.7%-12249.0pp	-6938.8%+9167.9pp	-16106.6%+95057.0pp	-111163.6%
Net Margin	-91866.0%+208719.7pp	-300585.7%-281225.7pp	-19360.0%-12060.8pp	-7299.2%+9463.2pp	-16762.4%+93228.5pp	-109990.9%
Return on Equity	N/A	-131.1%-50.7pp	-80.4%-34.9pp	-45.4%-7.6pp	-37.8%-6.6pp	-31.2%
Return on Assets	N/A	-106.4%-53.7pp	-52.6%-19.3pp	-33.4%-3.0pp	-30.4%-0.6pp	-29.8%
Current Ratio	N/A	3.14+1.0	2.16-3.8	5.92-13.0	18.95+5.4	13.51
Debt-to-Equity	N/A	0.47-0.0	0.51+0.3	0.16-0.0	0.19+0.1	0.05
FCF Margin	-47248.0%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-19810.0%	N/A	N/A	N/A	-78692.9%-48767.9pp	-29925.0%
Net Margin	N/A	N/A	-19478.0%	N/A	N/A	N/A	-78750.0%-48721.4pp	-30028.6%
Return on Equity	-25.5%+59.2pp	-84.7%-51.9pp	-32.8%	N/A	-31.3%-4.4pp	-26.9%+12.2pp	-39.1%-16.5pp	-22.5%
Return on Assets	-19.4%+45.5pp	-64.9%-39.1pp	-25.8%	N/A	-22.9%-4.3pp	-18.6%+5.0pp	-23.5%-8.8pp	-14.8%
Current Ratio	4.17-0.0	4.20+1.6	2.64-0.5	3.14+0.5	2.59+0.2	2.36+0.6	1.71-0.5	2.16
Debt-to-Equity	0.31-0.2	0.52+0.0	0.51+0.0	0.47+0.1	0.36-0.1	0.42-0.2	0.63+0.1	0.51
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Genenta Science Spa GNTA

$16.6M

Pds Biotechnology Corporation PDSB

$35.4M

Polypid Ltd. PYPD

$83.8M

JUPITER NEUROSCIENCES, INC. JUNS

$12.7M

Vtv Therapeutics VTVT

$162.2M

Frequently Asked Questions

What is Inmune Bio Inc's annual revenue?

Inmune Bio Inc (INMB) reported $50K in total revenue for fiscal year 2025. This represents a 257.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Inmune Bio Inc's revenue growing?

Inmune Bio Inc (INMB) revenue grew by 257.1% year-over-year, from $14K to $50K in fiscal year 2025.

Is Inmune Bio Inc profitable?

No, Inmune Bio Inc (INMB) reported a net income of -$45.9M in fiscal year 2025, with a net profit margin of -91866.0%.

What is Inmune Bio Inc's EBITDA?

Inmune Bio Inc (INMB) had EBITDA of -$47.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Inmune Bio Inc's operating margin?

Inmune Bio Inc (INMB) had an operating margin of -94766.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Inmune Bio Inc's net profit margin?

Inmune Bio Inc (INMB) had a net profit margin of -91866.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Inmune Bio Inc's free cash flow?

Inmune Bio Inc (INMB) generated -$23.6M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Inmune Bio Inc's operating cash flow?

Inmune Bio Inc (INMB) generated -$22.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Inmune Bio Inc's capital expenditures?

Inmune Bio Inc (INMB) invested $1.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Inmune Bio Inc spend on research and development?

Inmune Bio Inc (INMB) invested $20.7M in research and development during fiscal year 2025.

How many shares does Inmune Bio Inc have outstanding?

Inmune Bio Inc (INMB) had 27M shares outstanding as of fiscal year 2025.

Are Inmune Bio Inc's earnings high quality?

Inmune Bio Inc (INMB) has an earnings quality ratio of 0.49x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.